Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864384 | 0.97 | SMN1; SMN2 (0.32) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL6852245 | 0.94 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL8671685 | 0.94 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL6849263 | 0.94 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL2637189 | 0.94 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL879892 | 0.94 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL2780201 | 0.85 | — | — | |
| SCHEMBL2929810 | 0.83 | ATR (0.39) | — | |
| SCHEMBL2348807 | 0.83 | ESR1 (0.35) | — | |
| SCHEMBL866197 | 0.82 | SMN1; SMN2 (0.30) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079776-A | Method for synthesizing fulvestrant intermediate by utilizing pentafluoroethane photocatalysis and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-3947413-B1 | PROCESS FOR PURIFYING LIRAGLUTIDE | SCINOPHARM TAIWAN LTD (TW) | 2026-02-18 | — | — | EP | claimed |
| US-12269844-B2 | Process for purifying semaglutide and liraglutide | SCINOPHARM TAIWAN, LTD. (TW) | 2025-04-08 | — | — | US | claimed |
| CN-119431482-A | Method for preparing fulvestrant intermediate N-3 by one-pot method | 江西君业生物制药有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2024258458-A1 | HALOGENATED OLEFIN-CONTAINING POLYURETHANE FOAM-FORMING COMPOSITIONS, RELATED FOAMS AND METHODS FOR THEIR PRODUCTION | COVESTRO LLC (US) | 2024-12-19 | — | — | WO | claimed |
| CN-119031746-A | Composite material and preparation method thereof, photoelectric device and preparation method thereof, and display device | 广东聚华新型显示研究院 | 2024-11-26 | — | — | CN | claimed |
| CN-118930598-A | Fulvestrant Process for the preparation of intermediates | 杭州莱尼科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-114685593-B | Fulvestrant preparation method and fulvestrant intermediate | 鲁南制药集团股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116003500-A | Crystal form of fulvestrant intermediate and preparation method and application thereof | 杭州九源基因工程有限公司 | 2023-04-25 | — | — | CN | claimed |
| US-11459354-B2 | Process for purifying liraglutide | SCINOPHARM TAIWAN, LTD. (TW) | 2022-10-04 | — | — | US | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| EP-0909749-B1 | Process for the preparation of pentafluoropentanol | BAYER AG (DE) | 2002-08-28 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| US-6002053-A | Process for preparing pentafluoropentanol | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | claimed |
| WO-1999021860-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 1999-08-05 | — | — | WO | claimed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | claimed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| EP-0909749-A1 | Process for the preparation of pentafluoropentanol | BAYER AG (DE) | 1999-04-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459354-B2 | Process for purifying liraglutide | GLP1R, GCG, IAPP | SMN1; SMN2 3282/4885LMNA 3743/4885ALDH1A1 3453/4885 |
| US-12269844-B2 | Process for purifying semaglutide and liraglutide | GLP1R, GCG, DPP4 | SMN1; SMN2 2956/4885LMNA 4064/4885ALDH1A1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.